CME Group Inc. CME
Composite 51/100; the shares have moved about 28% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 33/100 — a moderate mark against it.
Quality ranks 66/100 — a moderate point in its favour. Growth ranks 62/100 — a moderate point in its favour. Balance-sheet strength ranks 51/100 — a slight point in its favour.
Valuation ranks 33/100 — a moderate mark against it. Income ranks 39/100 — a slight mark against it. Momentum ranks 44/100 — a slight mark against it.
What the company does CME Group operates global futures and options exchanges, clearing and settling trades across interest rates, equities, FX, commodities, and fixed income. It also provides market data services to institutional and individual investors, corporations, and governments.
Key financials CME reports strong profitability with ROE 15.8%, ROA 1.5%, and ROCE 14.5%. Net margins stand at 63.4% on revenue growth of 6.4% and EPS growth of 15.4%. Debt/equity is low at 0.15 and interest coverage is 29.74, supporting financial stability.
Stock health The stock shows mixed momentum: +5.02% over 3 months, -7.93% over 6 months, and +9.92% over 12 months. RSI(14) is elevated at 71.80, indicating potential near-term overbought conditions. Dividend yield is 1.8% with a payout ratio of 95.8%.
Price vs fair value CME trades at a PREMIUM of 1.00% versus the analyst mean target of 283.07. - Traders increased bets on rate hikes following hawkish Fed commentary (The Wall Street Journal) - September rate hike odds rose to 59% after Jackson Hole remarks (Benzinga Prediction Markets) - Analysts highlight CME’s stock performance amid volatility (Insider Monkey)
Looking forward Forward P/E of 21.79 and PEG of 5.63 suggest moderate earnings growth expectations. Sideravia scores Quality 65.5 and Growth 63.2, but Valuation 29.8 remains weak. Net margins and low leverage support resilience, though high payout may limit reinvestment.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.